Business Context and Reporting Period
This Form 8-K, dated December 23, 2024, reports the completion of the redomiciliation of Bionomics Limited (an Australian corporation) into Neuphoria Therapeutics Inc., a Delaware corporation. As of the Effective Date, Bionomics became a wholly-owned subsidiary of Neuphoria, which is now the ultimate parent company and successor issuer. Neuphoria is an emerging growth company.
Key Financial Metrics
This filing is a current report regarding a corporate restructuring and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes Versus Prior Period
- Corporate Structure: Bionomics Limited has been redomiciled to become a subsidiary of Neuphoria Therapeutics Inc.
- Securities Listing: Bionomics' American Depositary Shares (ADSs) were suspended from trading on Nasdaq and will no longer trade. Neuphoria's common stock is expected to commence trading on Nasdaq under the symbol "NEUP" on December 24, 2024.
- Share Conversion: Holders of Bionomics ordinary shares received one share of Neuphoria common stock for every 2,160 ordinary shares held. Holders of Bionomics ADSs received one share of Neuphoria common stock for every 12 ADSs held.
- Derivatives: Neuphoria issued new options and a warrant (covering 1,054,381 shares) to replace existing Bionomics options and warrants.
Guidance, Outlook, and Management Commentary
The filing does not provide financial guidance, revenue outlook, or management commentary on future performance. The primary focus is the legal and operational transition of the entity. Neuphoria has adopted a new Code of Conduct, an Equity Incentive Plan, and indemnification agreements for directors and officers. The Board of Directors is classified into three staggered terms expiring in 2025, 2026, and 2027.
Important Facts for Investor Verification
- Verify the trading start date and price of Neuphoria common stock (Symbol: NEUP) on Nasdaq, expected December 24, 2024.
- Confirm the CUSIP number for the new shares: 64136E102.
- Review the conversion ratios (1:2,160 for ordinary shares; 1:12 for ADSs) to ensure accurate share counts in brokerage accounts.
- Note that Bionomics has filed a Form 15 to terminate its registration and reporting obligations, with Neuphoria assuming all reporting duties.
- Identify the new transfer agent: Computershare Trust Company, N.A.